Verrica Pharmaceuticals Inc.VRCANASDAQ
Loading
Cash Generation ExpandingExpanding
Percentile Rank78
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-17.63M
↑ 29% vs avg
Percentile
P78
Within normal range
Streak
1 yr
Consecutive growthExpanding
Average
$-24.95M
Historical baseline
PeriodValueYoY Change
TTM$-17.63M+71.1%
2024$-60.95M-56.5%
2023$-38.94M-105.5%
2022$-18.95M+33.4%
2021$-28.46M+10.1%
2020$-31.68M-12.8%
2019$-28.09M-50.6%
2018$-18.65M-306.9%
2017$-4.58M-184.5%
2016$-1.61M-